Alterity Therapeutics Ltd Overview
Pro stress-test →Alterity Therapeutics is a clinical stage biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, focused on Multiple System Atrophy (MSA) and related Parkinsonian disorders. Results from Phase 2 trials demonstrated the drug to be safe and well-tolerated with strong signals of efficacy in an indication that currently has no approved disease-modifying treatments available.
Strategic Profile
Pro stress-test →The lead asset ATH434 has shown clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 trial in MSA and positive data in an open label Phase 2 trial in advanced MSA, with the company preparing to initiate a Phase 3 pivotal trial in MSA while developing a broader pipeline of compounds targeting neurological disease pathology. As of July 7, 2026, the company received official minutes from its End-of-Phase-2 meeting with the FDA regarding ATH434.
Competitive Landscape
Pro stress-test →Alterity operates in the rare neurodegenerative disease space where few approved therapies exist for MSA. Potential competitors include other biotech firms developing Parkinsonian disorder treatments and broader neurodegeneration programs, though MSA remains underserved with limited direct competition for this specific indication.
Industry Context
Alterity Therapeutics Ltd operates in Rare neurodegenerative disease therapeutics.
Key facts
Founded: N/A · Headquarters: Melbourne, Australia (with US operations in San Francisco) · Employees: N/A · Revenue: N/A · Market cap: N/A